期刊文献+

新型冠状病毒肺炎患者的心脏表现和治疗建议 被引量:19

Cardiac manifestations of patients with COVID-19 and related treatment recommendations
原文传递
导出
摘要 引起2002年严重急性呼吸综合征(SARS)和2012年中东呼吸综合征(MERS)的冠状病毒(CoV)被证实是从动物传播至人类的。而2019新型冠状病毒(2019-nCoV)引起了新型冠状病毒肺炎的暴发,则再次证明CoV对人类健康具有重大的威胁。2019-nCoV除感染呼吸系统外,研究报道其对心血管系统也有侵害作用。该文对2019-nCoV的基因组结构、功能以及感染者的病理生理学和心脏表型特征、心脏损伤的潜在机制、相关治疗策略进行了梳理,警示临床医生注意2019-nCoV对心脏的潜在风险、加强心脏功能管理。
作者 谭昭充 付灵华 王丹丹 洪葵 Tan Zhaochong;Fu Linghua;Wang Dandan;Hong Kui(Department of Cardiovascular Medicine,Second Affiliated Hospital of Nanchang University,Nanchang 330006,China;Jiangxi Key Laboratory of Molecular Medicine,Nangchang 330006,China)
出处 《中华心血管病杂志》 CAS CSCD 北大核心 2020年第6期434-438,共5页 Chinese Journal of Cardiology
  • 相关文献

参考文献6

二级参考文献28

  • 1胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:162
  • 2Hirsh J, Fuster V, Ansell J, et al. American Heart Association/ American College of Cardiology Foundation guide to warfarin therapy. J Am Coil Cardiol, 2003,41:1633-1652.
  • 3Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007, 146:S57-867.
  • 4Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coil Cardiol, 2008, 52: 865-868.
  • 5Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 2005,352:2285-2293.
  • 6Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353:717-719.
  • 7Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :eddS- 88S.
  • 8Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :e152S-184S.
  • 9Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics, 2010, 11 : 493 -496.
  • 10Schulman S, Parpia S, Stewart C, et al. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med, 2011,155:653-659.

共引文献2323

同被引文献182

引证文献19

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部